Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
Retrieved on:
Thursday, May 25, 2023
Biotechnology, General Health, Pharmaceutical, Health, Safety, Refractory, Science, Translational research, Update, Myeloproliferative neoplasm, Myelodysplastic syndrome, ALK, Center for International Blood and Marrow Transplant Research, Activin and inhibin, DLBCL, European Hematology Association, Research, Polycythemia vera, Combination therapy, S110, Chronic lymphocytic leukemia, Abstract, Combination, Chronic myelogenous leukemia, Cytokine release syndrome, ALL, CRS, Relapse, OPTIC, Lymphoma, MOST, Cancer, Diffuse large B-cell lymphoma, Neoplasm, ALK2, Abstract (summary), CML, PV, ASCO, BET, American Society of Clinical Oncology, EHA, Annual general meeting, Anemia, Society, Pharmaceutical industry, Communications satellite, Allotransplantation, Hydroxycarbamide, Primary myelofibrosis, Patient
ET)
Key Points:
- ET)
Phase 1b, Open-Label Study of Add-On Therapy with CK0804 in Participants with Myelofibrosis, with Suboptimal Response to Ruxolitinib (Abstract #TPS7087. - ET)1
A Phase 1/2 Study of Retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) Combination Therapy in Patients (Pts) with Advanced Solid Tumors (Abstract #2599. - ET)
Abstracts are available on the EHA2023 Congress platform and accessible for on-demand viewing until August 15, 2023. - ET)5
For full session details and data presentation listings, please see the ASCO ( https://conferences.asco.org ) and EHA2023 ( https://ehaweb.org/congress ) online programs.